JF
JNCE

Jump Financial’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Jump Financial’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-36,500
Closed -$111K – 2117
2022
Q2 		$111K Buy
+36,500
New +$178K ﹤0.01% 1428
2021
Q3 		– Sell
-60,942
Closed -$414K – 1626
2021
Q2 		$414K Buy
+60,942
New +$506K 0.04% 538
2021
Q1 		– Sell
-10,300
Closed -$72K – 1395
2020
Q4 		$72K Buy
+10,300
New +$80.2K 0.01% 887

Other funds holding JNCE

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Jump Financial's JNCE Position: Q3 2022 in Review

Jump Financial sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q3 2022, closing a stake of 36,500 shares — an estimated $111K sold.

Jump Financial first reported a position in JNCE in Q4 2020 and held it in 3 quarters. The position peaked at $414K in Q2 2021. 102 funds tracked by Wall St. Rank hold JNCE as of Q3 2022.

  • Jump Financial reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Jump Financial sold 36,500 Jounce Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $111K.
  • Jump Financial first reported a position in Jounce Therapeutics, Inc. Common Stock in Q4 2020 and held it in 3 quarters.
  • Jump Financial's Jounce Therapeutics, Inc. Common Stock position peaked at $414K in Q2 2021.
  • 102 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Jump Financial's 13F filing for Q3 2022, filed 7 Nov 2022.